Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 9:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 56 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: pupil dilation Clear all
Completed Not applicable Interventional Results available

Spectacles for Patients With Down Syndrome

NCT03367793
View directory record Official record
Conditions
Vision, Low
Interventions
Spectacles - Clinically Derived, Spectacles - Metric Technique #1 Derived, Spectacles - Metric Technique #2 Derived
Device
Lead sponsor
University of Houston
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2021 · Synced Sep 7, 2026, 9:42 AM EDT
Completed Phase 2 Interventional Results available

Pupil Dilation for Treatment of IFIS

NCT03760185
View directory record Official record
Conditions
Intraoperative Floppy Iris Syndrome
Interventions
Brimonidine Tartrate
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 100 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Sep 7, 2026, 9:42 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of the Safety, Efficacy and PK of EYN-1601 in Dilation of the Pupil

NCT02946125
View directory record Official record
Conditions
Mydriasis
Interventions
MDD-administered EYN-1601, Phenylephrine 2.5% Eyedrop, Phenylephrine 10% Eyedrop
Combination Product · Drug
Lead sponsor
Eyenovia Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Sep 7, 2026, 9:42 AM EDT
Enrolling by invitation Not applicable Interventional

Pupillary Dilation During Post-Auricular Vagal Nerve Stimulation

NCT05870527
View directory record Official record
Conditions
Hearing Loss
Interventions
Electrical stimulator
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 7, 2026, 9:42 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Wearing-Off Period of Pharmacological Dilation and Anisocoria

NCT05238233
View directory record Official record
Conditions
Anisocoria
Interventions
Tropicamide, 1% Pilocarpine, Proparacaine Hydrochloride, Tono pen AVIA, VG4 Gonio, Reichert phoropter
Drug · Device
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Sep 7, 2026, 9:42 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Medications for Opioid Use Disorder Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment

NCT06104280
View directory record Official record
Conditions
Opioid Use Disorder, Sleep Disturbance
Interventions
Post-Illumination Pupillary Response (PIPR), Polysomnography, Multiple Sleep Latency Test, Ecological Momentary Assessments, Actigraphy, DLMO, Melatonin Suppression Test
Other · Behavioral · Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 7, 2026, 9:42 AM EDT
Completed No phase listed Observational

Assessment of EyeArt Performance With Retinal Cameras

NCT04984200
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Retinal imaging, Mydriatic Agent
Procedure · Drug
Lead sponsor
Eyenuk, Inc.
Industry
Eligibility
22 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Idaho Falls, Idaho
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Sep 7, 2026, 9:42 AM EDT
Completed Not applicable Interventional Results available

Efficacy and Safety of AEYE-DS Software Device for Automated Detection of Diabetic Retinopathy From Digital Fundus Images

NCT04612868
View directory record Official record
Conditions
Diabetes Mellitus, Diabetic Retinopathy
Interventions
AEYE Software Device
Device
Lead sponsor
AEYE Health Inc
Industry
Eligibility
22 Years and older
Enrollment
531 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Sep 7, 2026, 9:42 AM EDT
Completed No phase listed Observational

Pilot Study of NeuroTriage Device in Patients with Potential Brain Injury And/or Impairment

NCT03761641
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Neurotriage
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 89 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Sep 7, 2026, 9:42 AM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation

NCT02652767
View directory record Official record
Conditions
Optic, Atrophy, Hereditary, Leber
Interventions
GS010, Sham Intravitreal Injection
Biological · Device
Lead sponsor
GenSight Biologics
Industry
Eligibility
15 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Los Angeles, California • Atlanta, Georgia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 7, 2026, 9:42 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis

NCT04024891
View directory record Official record
Conditions
Mydriasis, Dilation
Interventions
Phentolamine Mesylate Ophthalmic Solution 1%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Drug · Other
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
4
States / cities
Pittsburg, Kansas • Lexington, Kentucky • Athens, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Sep 7, 2026, 9:42 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Chromosome 18 Clinical Research Center

NCT00227253
View directory record Official record
Conditions
Chromosome Aberrations, Growth Hormone Deficiency, Hypomyelination
Interventions
Determination of growth hormone status, Measurement of growth, thyroid and sex hormone levels, Behavior and neuropsychometric evaluations, Audiological and ear, nose and throat examination, Magnetic resonance imaging of the brain, Dysmorphology evaluation, Neurology examination, Dental evaluation, Speech pathology evaluation, Psychiatric evaluation, Orthopedic evaluation, Ophthalmologic evaluation, Gastrointestinal evaluation
Procedure
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
Not listed
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1993 – 2040
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Sep 7, 2026, 9:42 AM EDT
Completed Not applicable Interventional

Efficacy and Safety of AEYE-DS Software Device for Automated Detection of Diabetic Retinopathy From Digital Funduscopic Images

NCT05857943
View directory record Official record
Conditions
Diabetes Mellitus, Diabetic Retinopathy
Interventions
AEYE-DS Software
Device
Lead sponsor
AEYE Health Inc
Industry
Eligibility
22 Years and older
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
3
States / cities
Fayetteville, Arkansas • Orlando, Florida • Jackson, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Sep 7, 2026, 9:42 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)

NCT05134974
View directory record Official record
Conditions
Mydriasis, Dilation
Interventions
Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophthalmic Solution Vehicle
Drug
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
12 Years and older
Enrollment
368 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
15
States / cities
Newport Beach, California • Westminster, California • Delray Beach, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Sep 7, 2026, 9:42 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Objectively Diagnose and Monitor Treatment of Light Sensitivity

NCT03694626
View directory record Official record
Conditions
Photophobia, Traumatic Brain Injury, Migraine
Interventions
Pupillography, Ocular Coherence Tomography (OCT), Wrist-watch sensor device, Videography, Electrophysiology
Device
Lead sponsor
Randy Kardon
Other
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Sep 7, 2026, 9:42 AM EDT
Terminated No phase listed Observational

Diagnosis of ON With or Without MS or NMOSD

NCT04131764
View directory record Official record
Conditions
Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder Attack, Neuromyelitis Optica Spectrum Disorder Relapse, Neuromyelitis Optica Spectrum Disorder Progression, Optic Neuritis
Interventions
Reflex (Brightlamp Inc., Purdue University)
Diagnostic Test
Lead sponsor
Jagannadha R Avasarala
Other
Eligibility
18 Years to 90 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Sep 7, 2026, 9:42 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Exploration of Pupil Dilation in Horner's Patients Taking Flomax

NCT03615508
View directory record Official record
Conditions
Horner Syndrome
Interventions
10% phenylephrine
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Sep 7, 2026, 9:42 AM EDT
Completed No phase listed Observational

Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool

NCT03112005
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Eye Problems, Diabetic Macular Edema
Interventions
Color fundus photography, Mydriatic Agent
Procedure · Drug
Lead sponsor
Eyenuk, Inc.
Industry
Eligibility
18 Years and older
Enrollment
942 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2018 · Synced Sep 7, 2026, 9:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sublingual vs IV Atropine Bioavailability Study

NCT04290039
View directory record Official record
Conditions
Toxic Effect of Organophosphate and Carbamate Insecticides
Interventions
Atropine Sulfate Ophthalmic Solution, Atropine Sulphate Injection
Drug
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 7, 2026, 9:42 AM EDT
Completed Not applicable Interventional

Study on Effective Mydriasis in Premature Infants

NCT01054027
View directory record Official record
Conditions
Retinopathy of Prematurity (ROP)
Interventions
1% phenylephrine and 0.2% cyclopentolate
Drug
Lead sponsor
Georgetown University
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 21, 2010 · Synced Sep 7, 2026, 9:42 AM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation (REVERSE)

NCT02652780
View directory record Official record
Conditions
Optic, Atrophy, Hereditary, Leber
Interventions
GS010, Sham Intravitreal Injection
Biological · Device
Lead sponsor
GenSight Biologics
Industry
Eligibility
15 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Los Angeles, California • Atlanta, Georgia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 7, 2026, 9:42 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pupillary Dilation Reflex in Healthy Volunteers

NCT07746167
View directory record Official record
Conditions
Healthy Participants
Interventions
No intervention (observational study)
Other
Lead sponsor
Children's National Research Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 7, 2026, 9:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Eyedrop Size on Pupillary Dilation Using the Nanodropper Bottle Adapter

NCT06689904
View directory record Official record
Conditions
Medication Delivery, Eye Drop Delivery
Interventions
Nanodropper, Standard eye drop bottle
Device
Lead sponsor
Sutter Health
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Sep 7, 2026, 9:42 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation

NCT03751098
View directory record Official record
Conditions
Mydriasis
Interventions
Tropicamide/Phenylephrine ophthalmic solution (TR/PE), Placebo
Drug
Lead sponsor
Eyenovia Inc.
Industry
Eligibility
Not listed
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Sep 7, 2026, 9:42 AM EDT